Advertisement
Advertisement
U.S. markets open in 2 hours 54 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Kala Pharmaceuticals, Inc. (KALA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.3317-0.0044 (-1.31%)
At close: 04:00PM EDT
0.3296 -0.00 (-0.63%)
Pre-Market: 06:34AM EDT
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • M
    MICHIELS
    I am staying far away from KALA - It looks like it is going to drop off a cliff. I actually get way better stocks at (http://Themaxgains.tech)
  • S
    Steve Stevens
    Probably one of the most boring conference calls I’ve listened to, only one caller at the end. Probably explains having $45m in cash, another $60m not recorded yet which equals over $100million in cash AND a $25million market cap, Not including the drug with high cure rates in an orphan designation which means NO Competitors. Definitely need some new leadership blood, horrible promoter,
  • c
    cash
    Long base support makes shares look attractive now. Also, this tiny microcap supported by early study could have diabetes breakthrough.
    https://richardacavalli.wixsite.com/greenplanetmicrocaps/new-diabetes-treatment
  • G
    GAN
    One fine morning - boom - buyout @$3 minimum

    Gl!
  • S
    Steve Stevens
    Its going to get very interesting once those alcon sales hit once we get past kala’s catastrophe at sales. Those 8 figure sales costs will disappear, the balance sheet will look alot better, really looking forward to it, however, the elephant in the room is nasdaq compliance which hasn’t been mentioned.
  • G
    Go Heels
    Company insiders at Kala have been selling shares .
    There are no insider purchases in the last 12 months.
    Seems those insiders who know the most ,know they don't want kala shares either.
    Bearish
  • G
    GAN
    Kind attn: CEO and the Board of Directors 

    As a shareholder who lost substantial amount of money I’m surprised and still don’t understand  why the Company should spend  $100 mln + in the next 2 years only going to be either failure or sold at a huge loss like it’s predecessor Drugs.

    Kala is Done shareholders lost over $700 mln in this failed experiment. 

    There is no point in any future development as we are not running a Government funded or non profit enterprise  since there is no way we could achieve viability in our experiments. Past work on both the Drugs proves that this Company is DESTINED TO FAIL FINANCIALLY.

    Company should Pay up the Remaining Debt and make it debt free and put the Drug which is on development for Sale. If there is no buyer it is very clear that the Street don’t see your idea a viable one, period. This is Common sense.

    Board should spin off the Royalty interest into a Trust along with the NOL and engage a reputed Trustee with definitive cost and expense information of running the Trust for the benefit of Shareholders.

    Alcon should be allowed to takeover the manufacturing plant and close out the shop by paying off the remaining cash to shareholders.

    As an experiment Kala is a Disaster and a total failure and it is time to call it off.

    Thanking you,
  • G
    GAN
    Any news?
  • G
    GAN
    Company should seek a partner or sell itself or simply wind up!

    Gl!
  • H
    HC
    They need to buy back the shares!
  • G
    GAN
    Added another 25 k shares - I own 100 k now. I’m convinced - on my own- given the orphan drug - potential of KPI012 anyone will buy these guys out.

    I’m not expecting much but definitely $3 is possible.

    It is less than an option price.

    Gl!
  • d
    david
    So their lender is Oxford Finance LLC a private equity lender. The interest rate is LIBOR plus 8...not a friendly FDIC Bank lender rate. The loans are collateralized by ALL company assets. This would include all IP...everything.

    They're not loan sharks...no thumbs will be broken when payment is delayed. They're at least one step above that but it's no surprise to me that the valuation is net of the debt valuing their assets at ZERO. After being roasted by this group there are no more Wall St Believers. Contemplating taking the hit and moving on myself as I cannot stand listening to these people and this MED guy who sounds like Mr Haney from Green Acres. lol
  • D
    Dan
    How long do they have before they get delisted?
  • d
    david
    Maybe RA throwing in the towel this morning.
  • G
    GAN
    Kala market cap @38 cents is under $30 mln

    Debt is 80 mln

    They will receive $60+ 15 mln = 75 mln

    Cash on hand = 70 mln

    Paying $40 mln debt.

    $329 mln expected royalty payments till 2029

    Kala should be minimum of $2

    Gl!
  • B
    BELLRICHARD
    Can’t find the right stocks to trade? I have the solution right here for free (http://market-engross.club)
  • G
    GAN
    Kind Attn: Mr. Mark Iwicki, Chairman & Board of Directors

    Dear Sirs,

    As a shareholder myself and as a CEO  yourself, we should all think whether we are running a commercial for profit enterprise or a charitable non profit organization.

    The company’s 2 commercial products were sold for $60 mln when the development costs were almost $700 mln. With the market being as is it is, time for the company to sell itself or wind down rather than spending money like a Drunken Sailor with the development of Unmarketable and unviable products. We are not an incubator or a company funded by Government grants or from any charity organization. This is a For Profit enterprise.

    At time as a CEO you need to look around and see what is left here instead of hemorrhaging further and further when there is absolutely no value left. Even if you develop any drug you can’t sell it profitably and it is time to call it quits.

    Hope better Common sense prevails at the top management level instead of destroying valuation further.
  • G
    GAN
    Company direction and stock value

    Kind Attn: Mr. Mark Iwicki, Chairman & Board of Directors

    Dear Sir,

    After pronouncement of Completion of Sale of 2 Approved assets and your future plans the Market has spoken and gave a THUMBS DOWN and it didn't like your grandiose plans for the Company.

    The company promised Heaven and Earth for both of its approved Drugs and spent nearly $700 MLN (Seven Hundred Million Dollars) in full and years of work only to be sold for a Paltry $60 mln with a very uncertain future Royalty Payments.

    I think the Company SHOULD WIND DOWN and SELL ITS REMAINING ASSET to some bigger pharma if there is a willing Buyer OR ABANDON the DEVELOPMENT if NONE is available which might prove the rest of the Industry don't believe and share in the Company's Management's vision and prospects  for this DRUG and  the Company should wind down, distribute the Remaining Cash to shareholders after Payment of remaining Debt.

    The Future Alcon Royalty Payables should be SPUN OFF along with the NOLs and assign to a Professional Management company so that the Shareholders can receive some benefit if and when Alcon achieves the milestones.

    As a Long term shareholder it is time for the Company to Cut its losses and save whatever is left since this experiment failed miserably and costed the shareholders lots of their wealth.

    Thanking you,
    Yours truly,
  • G
    GAN
    Having struck here will hold till a final outcome. Either Zero or Hero.

    This stem cell research if successful will be a jackpot. Someone should buy them
    Out for a decent value given the orphan drug designation

    Gl!
Advertisement
Advertisement